Results 171 to 180 of about 1,243,120 (289)

Two-Dimensional and Three-Dimensional Cartilage Model Platforms for Drug Evaluation and High-Throughput Screening Assays. [PDF]

Tissue Eng Part B Rev, 2022
Foster NC, Hall NM, Haj AJE.
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Correction: In silico drug evaluation by molecular docking, ADME studies and synthesis, characterization, biological activities, DFT, SAR analysis of the novel Mannich bases. [PDF]

BMC Chem
Tahiroğlu V, Gören K, Kotan G, Yüksek H.   +3 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

In silico drug evaluation by molecular docking, ADME studies and synthesis, characterization, biological activities, DFT, SAR analysis of the novel Mannich bases. [PDF]

BMC Chem
Tahiroğlu V, Gören K, Kotan G, Yüksek H.   +3 more
europepmc   +1 more source

A rat model for retinitis pigmentosa with rapid retinal degeneration enables drug evaluation in vivo. [PDF]

Biol Proced Online, 2021
Inoue C, Takeuchi T, Shiota A, Kondo M, Nshizawa Y.   +4 more
europepmc   +1 more source

A new and simple non-chromatographic method for isolation of drug/linker constructs: vc-MMAE evaluation

, 2017
Meghdad Abdollahpour‐Alitappeh, Mahdi Habibi‐Anbouhi, Saeed Balalaie, Farhad Golmohammadi, Majid Lotfinia, Mohsen Abolhassani   +5 more
openalex   +1 more source

Diagnostic evaluation of drug-resistant insular epilepsy

, 2019
R. G. Khachatryan, G. S. Ibatova, Т. М. Алексеева, W. А. Khachatryan   +3 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Manufacturing Uniform Cerebral Organoids for Neurological Disease Modeling and Drug Evaluation. [PDF]

Biomater Res
Hong H, Jun Y, Yoon SB, Park S, Lee J, Jang JW, Nam HJ, Cho H.   +7 more
europepmc   +1 more source